Russia's sovereign wealth fund has agreed on a deal to sell 100 million doses of its Covid-19 vaccine, Sputnik-V, to a major listed pharmaceutical company in India, Reuters reported, quoting a source close to the deal.

Clinical trials of the Russian vaccine in India are expected to follow and to be held jointly with this firm, the source said. Both the trials and supply deal depend on domestic regulatory approval.

RDIF will announce the name of the Indian firm later today, the source said.